Gustave Roussy, Cancer Campus, Grand Paris

This early-phase trial tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The study enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a s…

This study was designed to test whether adding tiragolumab to atezolizumab works better than atezolizumab alone for people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. It planned to include patients who had not received prio…

This study tests whether a precise, high-dose form of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therap…

This study tests a new drug called DS-1062a in about 100 people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. Participants must have already tried at least one but no more than three standard treatments. The drug is given every three we…

This study looks at whether removing only the thyroid gland works as well as also removing nearby lymph nodes in people with low-risk thyroid cancer. About 352 adults with small to medium-sized thyroid tumors will be randomly assigned to one of two surgeries. The goal is to see i…

This study tests whether giving immunotherapy (anti-PD1) before and after surgery, plus radiation, can help people with a rare head and neck melanoma stay cancer-free longer. About 60 adults with resectable tumors will receive the treatment and be followed for 2 years. The goal i…

This study tests the immunotherapy drug nivolumab in 45 children and adults with a rare type of blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment. Participants either have active disease (to see if the drug shrinks tu…

This study looks at whether a more intensive follow-up schedule after head and neck cancer treatment helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. Researchers will tr…

This study explores whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors choose the most effective treatment. About 152 adults with advanced, hard-to-treat solid tumors will have their organoids tested against a panel of drugs. The goal is to se…

This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS). Participants would have received either pembrolizumab alone or combined with olaparib before surgery, followed by more pembrolizumab after. The goal was to …